Activation of the TGFβ signaling pathway, especially in later stages of tumor progression, can result in the acquisition of mesenchymal features in cancer cells [54], increased resistance to chemotherapeutic agents [61], and can support immune evasion [70]. Here, TGFB1 is linked to neoplasm.